Journal article
A micro-costing analysis of post-fracture care pathways: results from the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)
J Talevski, KM Sanders, A Lal, JJ Watts, A Beauchamp, G Duque, F Borgström, JA Kanis, A Svedbom, SL Brennan-Olsen
Osteoporosis International | SPRINGER LONDON LTD | Published : 2022
Open access
Abstract
Summary: This study identified the costs and health-related quality of life impacts of several post-fracture multidisciplinary care pathways specific to individual skeletal site (hip, distal forearm, vertebrae, humerus). These care pathways may assist healthcare providers in allocating resources for osteoporotic fractures in more effective and cost-efficient ways. Introduction: This micro-costing study was undertaken to provide the estimated healthcare costs of several fracture site-specific health service use pathways associated with different trajectories of health-related quality of life (HRQoL) 12-months post-fracture. Methods: The study included 4126 adults aged ≥ 50 years with a fragil..
View full abstractGrants
Awarded by Amgen
Funding Acknowledgements
Open Access funding enabled and organized by CAUL and its Member Institutions JT was supported by an Australian National Health and Medical Research Council (NHMRC, of Australia) Postgraduate Scholarship (1151089). On its international level, the ICUROS is sponsored by Amgen, Eli Lilly, Medtronic, Novartis, SanofiAventis, Servier, and Pfizer. In Australia, the study was supported by the National Health and Medical Research Council with supplementary funding from Merck Pty Ltd. In Austria, the study was sponsored by Central Association of Austrian Social Security Institution, Austrian Society for Bone and Mineral Research (AuSBMR), Merck Sharp & Dohme, Servier GmbH, Medtronic GmbH, Amgen GmbH, Novartis GmbH, Nycomed GmbH, Roche GmbH, Sanofi-Aventis GmbH, and Daiichi-Sankyo GmbH. In Mexico, the study was supported by CONACyT. In Lithuania, the work was supported by the National Osteoporosis Center. In the USA, Amgen Inc., Ingenix Pharmaceutical Services, Eli Lilly and Company, Medtronic Spine LLC, and Pfizer (formerly Wyeth) sponsored the study. Hoffmann La Roche and Amgen provided support. In Estonia, the study was supported by the Estonian Science Foundation, and the Estonian Ministry of Education and Research. In Russia, the study was supported by Hoffmann La Roche, Amgen, and the Russian Osteoporosis Association.